- Home
- AREN vs ACRS Comparison
AREN vs ACRS Comparison
Compare AREN & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AREN | ACRS |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.8M | 230.8M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AREN | ACRS |
|---|---|---|
| Price | $3.89 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $9.75 |
| AVG Volume (30 Days) | 130.6K | ★ 1.4M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $142,815,000.00 | $15,742,000.00 |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | $13.81 | $6.06 |
| P/E Ratio | $1.58 | ★ N/A |
| Revenue Growth | ★ 6.72 | N/A |
| 52 Week Low | $1.05 | $1.05 |
| 52 Week High | $10.05 | $3.48 |
Technical Indicators
Market Signals| Indicator | AREN | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 56.58 |
| Support Level | $3.90 | $3.12 |
| Resistance Level | $4.40 | $3.23 |
| Average True Range (ATR) | 0.27 | 0.21 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 11.59 | 50.31 |
Price Performance
Historical ComparisonAbout AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.